文献速递造血干细胞移植与细胞治疗淋巴瘤

基于临床变量与细胞因子基因多态性的异基因造血干细胞移植后GVHD新型预测方法

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.
PubMed 文献 · Blood Adv · 2018-01-01

该研究在509例HLA全合同胞供者异基因造血干细胞移植患者中评估12个细胞因子基因的25个SNP,用线性回归和LASSO构建预测模型。包含临床与遗传变量的模型(CG-M)对3-4级急性GVHD的预测正确分类率为100%,显著优于仅遗传变量模型(88%)和仅临床变量模型(50%);CG-M与G-M对广泛型慢性GVHD的预测正确分类率为80% vs 66.7%,优于C-M。基于LASSO多因素分析计算的风险评分能正确分层3-4级aGVHD(P < .001)和广泛型cGVHD(P < .001)。

要点

  • CG-M对3-4级aGVHD的正确分类率为100%,G-M为88%,C-M为50%。
  • CG-M与G-M对广泛型cGVHD的正确分类率为80% vs 66.7%,优于C-M。
  • 基于LASSO多因素分析的风险评分可正确分层3-4级aGVHD和广泛型cGVHD(均P < .001)。

核心结论

  • 所提出的新型预测模型改善了allo-SCT后严重GVHD的预测,该方法可能有助于接受allo-SCT患者的个体化风险适配临床管理。

研究设计与样本

  • 研究纳入509例HLA全合同胞供者异基因造血干细胞移植患者,评估12个细胞因子基因中的25个SNP。
  • 数据采用线性回归模型和LASSO分析,通过随机选取85%病例(训练集)构建统计模型,基于剩余15%病例(测试集)确认预测能力。

主要发现

  • 包含临床与遗传变量的模型(CG-M)对严重aGVHD的预测显著优于仅含临床变量(C-M)或仅含遗传变量(G-M)的模型。
  • 对3-4级aGVHD,正确分类率(CCR1)为:CG-M 100%,G-M 88%,C-M 50%。
  • CG-M和G-M对广泛型cGVHD的预测优于C-M,CCR1分别为80% vs 66.7%。
  • 基于LASSO多因素分析计算的风险评分能正确分层发生3-4级aGVHD(P < .001)和广泛型cGVHD(P < .001)的患者。

关键数值与推荐

  • 3-4级aGVHD的CCR1:CG-M 100%,G-M 88%,C-M 50%。
  • 广泛型cGVHD的CCR1:CG-M与G-M为80% vs C-M 66.7%。
  • 风险评分分层3-4级aGVHD和广泛型cGVHD的P值均 < .001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disease (GVHD), its prediction remains unresolved and depends mainly on clinical data. The aim of this study is to build a predictive model based on clinical variables and cytokine gene polymorphism for predicting acute GVHD (aGVHD) and chronic GVHD (cGVHD) from the analysis of a large cohort of HLA-identical sibling donor allogeneic stem cell transplant (allo-SCT) patients. A total of 25 SNPs in 12 cytokine genes were evaluated in 509 patients. Data were analyzed using a linear regression model and the least absolute shrinkage and selection operator (LASSO). The statistical model was constructed by randomly selecting 85% of cases (training set), and the predictive ability was confirmed based on the remaining 15% of cases (test set). Models including clinical and genetic variables (CG-M) predicted severe aGVHD significantly better than models including only clinical variables (C-M) or only genetic variables (G-M). For grades 3-4 aGVHD, the correct classification rates (CCR1) were: 100% for CG-M, 88% for G-M, and 50% for C-M. On the other hand, CG-M and G-M predicted extensive cGVHD better than C-M (CCR1: 80% vs. 66.7%, respectively). A risk score was calculated based on LASSO multivariate analyses. It was able to correctly stratify patients who developed grades 3-4 aGVHD (P < .001) and extensive cGVHD (P < .001). The novel predictive models proposed here improve the prediction of severe GVHD after allo-SCT. This approach could facilitate personalized risk-adapted clinical management of patients undergoing allo-SCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Martínez-Laperche C, Buces E, Aguilera-Morillo MC, et al. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Adv. 2018. PMID: 30030270. doi:10.1182/bloodadvances.2017011502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。